| JGRQX | WCMLX | JGRQX / WCMLX | |
| Total Expense Ratio | 1.24 | 0.99 | 125% |
| Annual Report Gross Expense Ratio | 1.28 | 1.79 | 72% |
| Fund Existence | 9 years | 7 years | - |
| Gain YTD | 24.301 | 15.625 | 156% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 100000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 2.53B | 55.4M | 4,563% |
| Annual Yield % from dividends | 0.00 | 0.00 | - |
| Returns for 1 year | 25.09 | 26.07 | 96% |
| Returns for 3 years | 39.95 | 32.58 | 123% |
| Returns for 5 years | -14.74 | 1.14 | -1,288% |
| Returns for 10 years | N/A | N/A | - |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RSPG | 97.44 | 0.65 | +0.67% |
| Invesco S&P 500® Equal Weight Energy ETF | |||
| JMBS | 44.99 | 0.13 | +0.29% |
| Janus Henderson Mortgage-Backed Sec ETF | |||
| DSCO | 24.81 | 0.05 | +0.20% |
| DoubleLine Securitized Credit ETF | |||
| ITDD | 38.43 | 0.07 | +0.18% |
| iShares LifePath Target Date 2040 ETF | |||
| LFSC | 44.97 | N/A | N/A |
| F/m Emerald Life Sciences Innovation ETF | |||